e-therapeutics plc (LON:ETX – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 9.48 ($0.12) and traded as low as GBX 9 ($0.11). e-therapeutics shares last traded at GBX 9 ($0.11), with a volume of 2,518,125 shares trading hands.
e-therapeutics Price Performance
The firm has a market capitalization of £52.59 million, a P/E ratio of -450.00 and a beta of 0.46. The business has a 50-day moving average of GBX 9 and a 200 day moving average of GBX 9.45. The company has a current ratio of 22.20, a quick ratio of 20.13 and a debt-to-equity ratio of 0.33.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
See Also
- Five stocks we like better than e-therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Top-Performing Non-Leveraged ETFs This Year
- Golden Cross Stocks: Pattern, Examples and Charts
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
